Clinical Trials Browser

Phase 2/3 × INDUSTRY × Rituximab × Clear all

NCT05139017 2026-05-22

waveLINE-003

Phase 2/3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2/3 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02763319 2025-07-17

B-MIND

Phase 2/3 Completed

453 enrolled 29 charts

Lymphoma, Large B-Cell, Diffuse

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2/3 Completed

111 enrolled 20 charts

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01277172 2011-01-14

TREND

Phase 2/3 Unknown

Immunoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

NCT00045877 2006-02-06

Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments

Phase 2/3 Completed

Lymphoma, Follicular, Lymphoma, Non-Hodgkin